Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 6Terminated 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 2Uveal Melanoma 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Terminated × siremadlin × Clear all
NCT03940352 2025-10-10

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Novartis

Phase 1 Terminated
52 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04496999 2022-10-06

HDMM

Insel Gruppe AG, University Hospital Bern

Phase 1 Terminated
2 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02601378 2022-09-29

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

Novartis

Phase 1 Terminated
107 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡